SCCYF - Scythian Biosciences Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
2.4500
-0.0900 (-3.54%)
At close: 3:48PM EDT
Stock chart is not supported by your current browser
Previous Close2.5400
Open0.0000
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume293,015
Market Cap119.434M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.01
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire2 months ago

    Scythian Biosciences Announces Name Change to SOL Global Investments Corp.

    The Company’s shareholders approved the name change at a special meeting of shareholders held on September 14, 2018. In connection with the name change, the Company has applied to change its trading symbol on the Canadian Securities Exchange from “SCYB” to “SOL”. The common shares of the Company are expected to begin trading on the Canadian Securities Exchange under the new symbol on or about October 29, 2018.

  • GlobeNewswire2 months ago

    Scythian Biosciences Makes Strategic Investment in Verano™ Holdings with $188 Million USD Transaction

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl:SCCYF) is pleased to announce a USD$88 million investment in Class B units in Verano Holdings, LLC (“Verano”), a private, Delaware organized, vertically integrated, licensed operator of cannabis cultivation, manufacturing and retail facilities across six key U.S. states and Puerto Rico.  Scythian has also agreed to sell a 100% interest in 3 Boys Farms LLC (“3 Boys Farms”), which it will acquire as described below, to Verano in exchange for USD$100 million of Class B units in Verano. All transactions related to 3 Boys Farms are subject to the receipt of all required governmental approvals including from the Florida Department of Health, Office of Medical Marijuana Use (“Florida OMMU”).

  • GlobeNewswire2 months ago

    Scythian Biosciences Applauds the UK Government’s Decision to Legalize Medical Cannabis

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl:SCCYF) applauds the United Kingdom’s decision to allow specialist doctors the option to legally issue prescriptions for cannabis-based medicines when they believe patients could benefit from the treatment. The law change, passed in Parliament yesterday, came after Home Secretary Sajid Javid listened to concerns from parents of children with conditions such as severe epilepsy.

  • GlobeNewswire2 months ago

    Scythian Biosciences Announces Major Milestone in U.S. Expansion

    Chris, Formerly with Incredibles, One of the Industry’s Leading Vape, Extracts and Wellness Companies, Has Nearly Two Decades of Experience in Greenhouse Architecture, Management and Cultivation. TORONTO, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl:SCCYF) today announced the  Florida Department of Health, Office of Medical Marijuana Use (“DOH”) has approved the transfer of 60% of the Equity of 3 Boys Farms, LLC. (“3 Boys Farms”) to CannCure Investments Inc. (“CannCure”) including 3 Boys Farms’ license to operate as a Medical Marijuana Treatment Center in Florida.

  • GlobeNewswire2 months ago

    Scythian Biosciences Announces Intention to Commence Normal Course Issuer Bid to Repurchase up to 5% of its Common Shares

    Scythian Biosciences Corp. (“Scythian” or the “Company”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl: SCCYF) announced its intention to commence a normal course issuer bid (“NCIB”), under which the Company may purchase up to 2,451,861 of the Company’s common shares, representing approximately 5% of its issued and outstanding common shares (the “Shares”). The Company is commencing the NCIB because it believes that, from time to time, the market price of its Shares may not fully reflect the underlying value of the Company’s business and future prospects.

  • GlobeNewswire3 months ago

    Scythian Biosciences Closes Strategic Sale of Latin American and Caribbean Assets

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl: SCCYF) has closed its strategic sale of the Company’s Latin American and Caribbean assets to Aphria Inc. (APH.TO) (“Aphria”), a leading global cannabis company. This sale will provide Scythian with leverage for early stage investments in emerging U.S. markets.

  • GlobeNewswire3 months ago

    Scythian Biosciences Closes Acquisition of MMJ International Investments Inc.

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl: SCCYF) has completed its acquisition of MMJ International Investments Inc. (“MMJ International”), a privately-held British Columbia company that owns 100% of ABP S.A. (“ABP”), a pharmaceutical import and distribution company with a license to import, sell and distribute medical products and derivatives in Argentina (the “Acquisition”).

  • GlobeNewswire3 months ago

    Scythian Biosciences Announces Successful Results of Special Meeting of Shareholders

    Shareholders Approve Name Change to SOL Investments Corp. TORONTO, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl: SCCYF) is pleased to announce the results of Scythian’s special meeting of shareholders on September 14, 2018 (“Special Meeting”).

  • GlobeNewswire3 months ago

    Scythian Biosciences Announces Execution of Share Purchase Agreement with MMJ International Investments Inc., owner of Argentina-based ABP S.A.

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl: SCCYF) announces that it has entered into a definitive share purchase agreement (the “Purchase Agreement”) with MMJ International Investments Inc. (“MMJ”), a privately-held British Columbia company and all of the shareholders of MMJ, to acquire all of the issued and outstanding common shares of MMJ (the “Acquisition”).  MMJ is the owner of Argentina-based ABP S.A. (“ABP”), a pharmaceutical import and distribution company with a license to import, sell and distribute medical products and derivatives in Argentina. ABP also holds a license to import cannabidiol oil into Argentina. The Purchase Agreement supersedes the previously-announced business combination agreement between Scythian and MMJ to effect the Acquisition.

  • Newsfile4 months ago

    CSE New Listing - Scythian Biosciences Commences Trading on the Canadian Securities Exchange - Video News Alert on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - August 16, 2018) - Scythian Biosciences Corp. (CSE: SCYB) (FSE: 9SB) (OTCQB: SCCYF) is the latest new listing on the Canadian Securities Exchange, having previously traded on the TSX Venture Exchange. Scythian is an international cannabis company with a focus on the world's leading markets outside of Canada.Cannot view this video? Visit:http://www.investmentpitch.com/video/0_iqfkmq3h/Scythian-Biosciences-Corp-CSESCYB-New-ListingInvestmentPitch Media has produced a "video" which provides a brief overview of the company. If this link ...

  • The Global Cannabis Market Is Set To Explode
    Oilprice.com5 months ago

    The Global Cannabis Market Is Set To Explode

    2018 saw the North American cannabis market explode, peaking when Canada announced it will fully legalize recreational use, but the opportunities for this commodity are only just beginning